Devices and methods for endoscopic neuroablation in the tympanic cavity
The endoscopic device for neural ablation in the middle ear addresses the complexity of middle ear pathologies by allowing precise, minimally invasive nerve targeting, effectively treating otalgia, taste disturbances, and obesity through temporary nerve disruption and regeneration, while reducing trauma to surrounding structures.
Patent Information
- Application Number
- PCT/US2023/022766
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for treating middle ear pathologies such as otitis media, otalgia, headache, neurogenic inflammation, obesity, and facial hyperhidrosis are invasive and often ineffective, particularly in addressing the complex neural innervation of the tympanic cavity, which complicates precise targeting and minimization of trauma to surrounding structures.
A minimally invasive endoscopic device and method for targeted neural ablation in the middle ear using energy-based modalities like heat or freezing, allowing for precise ablation of nerves within the tympanic cavity without raising a tympanic flap, thereby minimizing trauma and enabling treatment of various dysfunctions caused by nerve malfunctions.
The approach enables effective management of middle ear-related disorders by temporarily disrupting misfiring nerves, promoting neural regeneration and reducing symptoms such as otalgia, taste disturbances, and obesity, while minimizing damage to other ear structures and improving surgical precision.
Smart Images

Figure US2023022766_21112024_PF_FP_ABST
Abstract
Description
DEVICES AND METHODS FOR ENDOSCOPIC NEUROABLATION IN THE TYMPANIC CAVITYBACKGROUND OF THE INVENTION
[0001] The middle ear cavity, also known as the tympanic cavity, is an air-filled chamber in the petrous part of the temporal bone. It is separated from the external ear by the tympanic membrane, and from the inner ear by the medial wall of the tympanic cavity. It contains the three auditory ossicles whose purpose is to transmit and amplify sound vibrations from the tympanic membrane to the oval window of the lateral wall of the inner ear.
[0002] Middle ear ossicles consist of three small bones (the malleus, incus and stapes), which form a mobile chain across the tympanic cavity from the tympanic membrane to the oval window. There are two muscles, one attached to the malleus, and one attached to the stapes, which act to damp down over-vibration from low-pitched sound waves. The tensor tympani muscle inserts into the handle of the malleus, and stapedius muscle inserts into the neck of the stapes.
[0003] A. MIDDLE EAR INNERVATION
[0004] Al. CHORDA TYMPANI
[0005] The chorda tympani, a branch of nervus intermedius, leaves the facial nerve in the facial canal and enters the tympanic cavity through the posterior wall, lying just underneath the mucous membrane. It runs over the pars flaccida of the tympanic membrane, and the neck of the malleus. It leaves at the anterior margin of the tympanic notch. The chorda tympani carries special visceral afferent fibers that relay sensations of taste from the anterior portion of the tongue. Additionally, it carries parasympathetic general visceral efferent fibers to the submandibular ganglion, which then innervate the sublingual and submandibular glands. The chorda tympani's efferent parasympathetic fibers cause vasodilation of blood vessels in the tongue.
[0006] Damage to the chorda tympani nerve can occur due to inflammatory diseases of the middle ear such as otitis media and cholesteatoma. It can also result from medication use, radiotherapy, viral infection, Bell’s Palsy, or due to surgical intervention in the middle ear. Damage to the chorda tympani, regardless of cause, can result in impaired secretion ofthe lacrimal, submandibular, and sublingual glands, and decreased taste sensitivity or distortions in taste perception. In other conditions, for example in case of excessive drooling, the reduced function of the chorda tympani might be desirable. Pathologies associated with the function of chorda tympani include, but are not limited to phantom taste, retronasal olfaction, obesity (hypoactive chorda tympani), and burning mouth syndrome.
[0007] A2. JACOBSON’S NERVE
[0008] The tympanic branch of the glossopharyngeal nerve (Jacobson’s nerve) forms the tympanic plexus by combining with sympathetic fibers from the internal carotid plexus (caroticotympanic nerves) and a small communicating branch with the geniculate ganglion of the facial nerve. The caroticotympanic nerves supply the eardrum ("tympanum") and carotid canal. They are the postganglionic sympathetic fibers from internal carotid plexus which enter the tympanic cavity via the caroticotympanic artery. The tympanic plexus gives off the lesser petrosal nerve (LPN), which provides parasympathetic innervation to the parotid gland via the otic ganglion. The LPN originates at the region of the geniculate ganglion and carries mainly preganglionic parasympathetic fibers from the tympanic plexus to the parotid gland. Although its largest source of fibers is from the tympanic branch of the IX, the LPN is actually the result of a composition of fibers contributed by three different nerves: 1) the tympanic branch of the IX, 2) the nervus intermedius of the VII, and 3) the auricular branch of the X (Arnold’s nerve) (Mavridis & Pyrgelis, 2016).
[0009] The preganglionic parasympathetic fibers synapse with the cell bodies of the postganglionic parasympathetic fibers in the otic ganglion (OTG). The sympathetic fibers that join the nerve from the middle meningeal artery pass right through the OTG. The postganglionic parasympathetic secretomotor fibers from the OTG pass to the parotid salivary gland through the auriculotemporal nerve which lies in contact with the deep surface of the gland (Mavridis & Pyrgelis, 2016). The auricotemporal nerve continues to innervate the temporomandibular joint and part of the ear drum and the external ear canal.
[0010] A3. ARNOLD’S NERVE
[0011] The auricular branch of the vagus nerve (Arnold’s nerve) conveys sensation from the tragus and external acoustic meatus. It is a mixed general somatic afferent nerve composed of vagal, glossopharyngeal, and facial nerve fibers. Arnold’s nerve is the remnant of the embryonic nerve that supplies the first branchial arch, which includes the externalacoustic meatus, middle ear and auditory tube. This nerve enters the temporal bone on the external surface of the jugular fossa and runs horizontally where a small branch unites it with the facial nerve. Turning around the posterior aspect of the facial nerve, it comes to be immediately behind the chorda tympani to which it connects then turns more abruptly downwards and leaves the bone through a small foramen close to the stylomastoid foramen. Laryngeal cancer and myocardial infarction can both present with pain behind the ear and in the ear - this is a referred pain through the vagus nerve to Arnold’s nerve.
[0012] A4. FACIAL NERVE
[0013] The labyrinthine segment of facial nerve begins after the facial nerve has passed through the internal acoustic meatus. After the internal acoustic meatus, the motor root of the facial nerve, and the nervus intermedius enters the facial canal passing between the cochlea and vestibule before bending posteriorly at the geniculate ganglion, at which point the motor root and nervus intermedius join. The labyrinthine segment gives off three branches including the greater superficial petrosal nerve which contains parasympathetic fibers for the lacrimal gland and taste fibers from the palate. The tympanic segment of the facial nerve (VII) begins as the facial nerve passes posteriorly at the geniculate ganglion. This segment is in the medial wall of the middle ear cavity, directly below the lateral semicircular canal. The mastoid segment begins after the tympanic segment moves downwards, distal from the pyramidal eminence of the middle ear cavity. From here, the mastoid segment travels through the facial canal and up to the stylomastoid foramen. This segment gives off three branches: the nerve to stapedius muscle, the chorda tympani (containing parasympathetic fibers to sublingual and submandibular salivary glands and taste fibers from the anterior two-thirds of the tongue), and the sensory branch which joins the auricular branch of the vagus nerve. The sensory branch carries general somatic afferent fibers from the pinna and the external auditory meatus (Seneviratne & Patel, 2022).
[0014] B. MIDDLE EAR NEURAL PATHOLOGIES
[0015] Bl. OTITIS MEDIA
[0016] Otitis media is a group of inflammatory diseases of the middle ear. One of the two main types is acute otitis media, an infection of rapid onset that usually presents with ear pain. The other main type is otitis media with effusion which is defined as the presence of non-infectious fluid in the middle ear which may persist for weeks or months. Otitis mediawith effusion is typically not associated with symptoms, although occasionally a feeling of fullness is described. Chronic suppurative otitis media is middle ear inflammation that results in a perforated tympanic membrane with discharge from the ear for more than six weeks.
[0017] Both immune and peripheral nervous systems are involved in both the acute and chronic phases of otitis media. The middle ear has an abundance of immune cells (such as mast cells), sensory neurons, and vasculature, which collectively participate in the immunological response of the ear to environmental stimuli. Upon stimulation or pathogen encounter, the sensory neurons release neuropeptides, mostly substance P and CGRP to activate the immune system. In response to the neuropeptide release, mast cells release cytokines (such as TNF beta) as part of a defense mechanism. The neuropeptides then act on cytokines to induce positive feedback of inflammation.
[0018] It has been shown in animal and in vitro models that selectively ablating sensory neurons is effective in preventing formation of middle ear effusion or to treat ear hypersensitivity. Such selective ablation has also been shown to have positive effect on preventing bone remodeling due to middle ear infection and inflammation. This research is in its infancy and methods for causing such selective neurulation in humans and its potential efficacy have not been studied or contemplated.
[0019] B2. OTALGIA
[0020] The internal, middle and external ear are also supplied by branches of the trigeminal, facial, glossopharyngeal and vagus nerves which can result in referred pain in the ear from other areas supplied by these nerves, e.g., the teeth, the posterior part of the tongue, the pharynx, the larynx, or the temporomandibular joint.
[0021] Otalgia or earache is a common and indiscriminate affliction, affecting persons of all ages. When the cause of otalgia can be identified to be localized to the affected ear, it is referred to as a primary otalgia. Common causes of primary otalgia include otitis media, external otitis, folliculitis, cerumen impaction, mastoiditis, myringitis, and neoplasm. When the source of the pain cannot be localized to the affected ear, it is referred to as secondary or referred otalgia. Because of the complex interplay of multiple upper cervical, lower cranial, and peripheral nerves providing sensory information to and from the ear, localizing the source of referred ear pain is challenging. This complexity is magnified by the diverse anatomic territory innervated by these nerves, which spans portions of the brain,spine, skull base, aerodigestive tract, salivary glands, paranasal sinuses, face, orbits, deep spaces of the neck, skin, and viscera.
[0022] Any irritative focus such as tumor, infection, or inflammation of structures within the oral cavity (specifically including the floor of mouth, cheek, anterior tongue, hard palate, and sublingual and submandibular glands), lower teeth, mandible including the temporomandibular joint (TMJ), and parotid glands can all be sites of distant pathology resulting in referred otalgia. Dental diseases account for most pathology causing referred otalgia. Otalgia is listed as a chief complaint by 70%-78% of patients with TMJ disorders. It is unclear whether this is a true reflex referred ear pain secondary to direct impingement of the auriculotemporal nerve related to masseteric muscle spasm, or secondary to a direct ligamentous connection between the TMJ and middle ear, but one or all of these theories may potentially explain TMJ pathology resulting in otalgia (Chen et al., 2009).
[0023] Essentially any pathology residing within the sensory net of cranial nerves V, VII, IX, and X and upper cervical nerves C2 and C3 can potentially cause referred otalgia (Chen et al., 2009).
[0024] Division of Jacobson’s nerve, or tympanic neurectomy, has been used as a successful treatment for referred otalgia. Tympanic neurectomy was first proposed by Lempert in 1946 for the treatment of tinnitus and was named “Tympanosympathectomy” (LEMPER, T, 1946). Because this procedure failed to relieve tinnitus, it was not further considered. In 1952, Rosen elicited the pain in two patients by stimulating Jacobson’s nerve with an electrode (Rosen, 1952). Resection of the tympanic plexus in both patients led to complete resolution of their symptoms after which an additional series supported the success of this technique (Rosen, 1952).
[0025] The procedure was then described by Golding-Wood in 1962 and again repeated in 1990 by Cook et al. (Cook et al., 1990; Golding-Wood, 1962). In these published cases, referred otalgia was relieved following a tympanotomy with 2 mm of the tympanic nerve excised (Cook et al., 1990). In 2016, the procedure was revisited by Roberts et. al. who performed a microscopic tympanic neurectomy on twelve patients showing improvement in intractable otalgia (Roberts et al., 2016).
[0026] In the reported procedures, an operative microscope was used to raise a tympanomeatal flap. A section of Jacobson’s nerve was then surgically removed. Thetympanomeatal flap was returned and sutured to the posterior canal, and packing was placed in the external ear canal.
[0027] B3. HEADACHE
[0028] Nerve projections from the superior cervical ganglion (SCG), dorsal root ganglia (DRG) and otic ganglion (OTG) onto cerebral arteries have shown to contain neurotransmitters that can participate in migraine pathology. The effects of these ganglia have been investigated less intensively compared to that of the trigeminal ganglion and sphenopalatine ganglion (SPG) with respect to primary headaches (White et al., 2021). In addition to the ophthalmic branch of the trigeminal nerve, the maxillary (V2) and mandibular (V3) branches of the trigeminal nerve also participate in sensory innervation of the cerebral arteries and middle cranial fossa. Meningeal branches of V2 and V3 run along with branches of the middle meningeal artery (MMA). These intracranial branches also receive afferents from peri-cranial temporal, parietal, and occipital periosteum, and adjacent deep layers of the temporal and upper neck muscles, that could result in tension type headaches upon stimulation (Uebner et al., 2014). While V2 and V3 provide sensory innervation to MMA, superior cervical ganglion provides sympathetic innervation to this artery. Meanwhile, SPG and otic ganglion (OTG) provide MMA with parasympathetic innervation (Edvinsson et al., 1989; Uddman et al., 1989)
[0029] The sensitization of sensory neurons innervating MMA can result in a parasympathetic reflex arc, resulting in release of parasympathetic neurotransmitters such as VIP and PCAP from SPG and OTG which results in further vasodilation and prolongation of pain. The sympathetic / parasympathetic imbalance could similarly result in cerebral vasodilation which can lead to headache and migraine.
[0030] The parasympathethic feed into the OTG is formed within the tympanic cavity where branches of tympanic branch of the glossopharyngeal nerve mix with the sympathetic branches from the internal carotid artery and branches from the facial nerve to form a plexus. The plexus sends preganglionic parasympathetic fibers which synapse in the OTG to form post-synaptic parasympathetic fibers which then innervate MMA in addition to providing parasympathetic innervation to all branches of V3. While blocking SPG has been explored in treating migraine, it is reasonable to assume that blocking OTG or itsparasympathetic fibers could potentially provide pain relief at least for a subset of migraine patients.
[0031] B4. NEUROGENIC INFLAMMATION
[0032] Inflammatory diseases in temporomandibular joint such as arthritis have been shown to results in increase in CGRP content in the trigeminal ganglia and the increased vasoactive intestinal peptide (VIP) accumulation in the Otic ganglion (Carleson et al., 1997). In case of inflammatory diseases of neurogenic origin disconnecting the parasympathetic outflow to the inflamed organ reduces vasodilation and can therefore terminate the inflammatory cascade. Similar strategy has been used in treatment of inflammatory diseases of the upper airways where cutting the parasympathetic outflow has resulted in relief from symptoms e.g. in case of ablation of posterior nasal nerve in treating vasomotor rhinitis or in treating migranious headache. Therefore, it is hypothesized that ablation of tympanic plexus with special interest in depleting its parasympathetic content could provide a potential treatment option.
[0033] B5. OBESITY
[0034] The relationship between taste and obesity is complex. The ability to detect a tastant is hypothesized to be weakened by obesity and obese individuals report taste hyposensitivity. One potential candidate for decreased orosensory fat perception is the innervation of lingual fat receptors. Two nerves carry information from papillae to the central nervous system for further processing — the chorda tympani (CT) and the glossopharyngeal (GL). The CT primarily innervates the fungiform papillae and the anterior foliate papillae. The GL innervates the posterior foliate and the circumvallate papillae. In the clinical population, damage to either the CT, from repeated episodes of otitis media, or GL damage from head and neck pathology, lead to decreased taste sensation and increased likelihood of obesity (Schreiber et al., 2020).
[0035] The “oral disinhibition” or “release of inhibition” model has been put forward, in which the sensory nerves of the mouth partially and mutually suppress one another, so that damage to one nerve disinhibits those that remain, resulting in increased activity that effectively compensates for regional loss. In human experiments, CT anesthesia enhances taste cues on the contralateral posterior tongue (innervated by IX). Other observations indicate that glossopharyngeal nerve loss drives CT disinhibition in a similarmanner, and that damage to either nerve leads to elevated somatosensory input from the trigeminal nerve (Snyder & Bartoshuk, 2016).
[0036] In a recent study Schriber et al have shown that hyposensitive and / or dysregulated orosensory perception of highly palatable foods contribute to the susceptibility to develop obesity and that simultaneous sectioning of both CT and GL can overcome the compensatory effect on each other and effectively reduce fat intake in obesity prone rats (Schreiber et al., 2020).
[0037] B6. FACIAL HYPERHIDROSIS
[0038] Hyperhidrosis (is defined as sweating exceeding the necessary amount to meet the body’s thermal regulation and physiological needs. It is characterized by excessive sweating in a specific region due to sweat gland hyperfunctioning, directly affects quality of life, and compromises the patient emotionally, socially, and professionally. Facial hyperhidrosis can be a result of hyperfictional parasympathetic innervation to the parotid gland which is provided through the tympanic plexus.
[0039] B7. TEMPORAL BONE HYPER PNEUMATIZATION
[0040] Hyper pneumatization of the temporal bone or mastoid cells within the ear cavity can results in exposure of nerves that are normally encased in bony canals such as facial nerve. Symptoms observed in these cases depend on the exposed nerves and their field of innervation.
[0041] PROCEDURE
[0042] An operating microscope is typically used when performing middle ear surgery because of its ability to illuminate and magnify the surgical field. However, these microscopes only provide a line-of-sight image with a narrow field of view that is limited by the size and shape of the external auditory canal. The use of microscopes also require elevation of the tympanic membrane to access and facilitate line of sight visualization of the middle ear structures. Endoscopes overcome many of these limitations providing a non-line- of-sight view that is less limited by port size and shape, with both illumination and image capture taking place at the distal tip of the scope near the surgical field.
[0043] Neurectomy, neurolysis, or destruction of neural tissue, can be performed surgically under direct visualization as conducted in the previously described tympanic neurectomy cases. As advancements in imaging and ablative techniques continue to progress, these procedures can now be done chemically, thermally via heating (e.g., application of radiofrequency, microwave, or laser energy) or via freezing (e.g. using cryoneurolysis). Using these ablative techniques especially in combination with an imaging modality allows these complex procedures to be performed on a precise target without the need for extensive or more invasive surgery to create surgical access to the targeted middle ear anatomy.
[0044] There is limited prior work in using freezing or cryogenics for neurolysis and / or ablation in the tympanic cavity. House et al. investigated applying cryosurgery to the promontory or the horizontal canal of the tympanic cavity to selectively destroy the vestibular portion of the labyrinth by creating a perilymph-endolymph shunt or fistula to treat Meniere’s disease (House, 1966). However, this technique did not result in any significant advantage over other known treatment modalities. Consistent with observations made by House, Bernstein and Friedmann saw little histological change in the labyrinth of a squirrel monkey after cryo application to the promontory (Bernstein & Friedmann, 1969). Due to lack of clinical efficacy, this specific application of cryosurgery in the tympanic cavity was not pursued further. To clarify, the ablation procedure discussed by these authors was not intended to ablate a nerve within the tympanic cavity.
[0045] The current invention describes an ablation device and its minimally invasive method of use to perform targeted neural ablation procedures in the middle ear with or without direct visualization. It also teaches devices and methods for transtympanic nerve ablation within the middle ear cavity without raising a tympanic flap and therefore leaving the tympanic membrane largely intact and minimizing trauma to other nerves in the middle ear cavity.
[0046] It is contemplated that the devices and methods of the invention described herein will enable practitioners to manage or treat several diseases and dysfunctions caused by the malfunctioning of the nerves passing through the tympanic cavity including secondary otalgia and taste disturbances. These outcomes can be achieved by temporary, minimally invasive neuroablation of middle ear nerves with or without direct visualization. It is contemplated that the temporary neural damage caused by the ablation will “disconnect” amisfiring nerve prompting neural regeneration. The newly regenerated nerve would lack the dysfunction and therefore resolve the affliction.
[0047] Use of the methods and devices described herein allow for surgical operations on middle ear nerves without damaging other middle ear structures, reducing the risk of these procedures. Additionally, use of energy -based ablation modalities such as heat or freezing allow for a larger section of the nerve to be ablated compared to single point nerve dissection, increasing the efficiency of the procedure, as non-ablated remnants of a nerve can compensate for the injured section and continue to transmit pain or send aberrant signals rendering the procedure less effective.SUMMARY OF THE INVENTION
[0048] In one embodiment, the device comprises a proximal end and distal end connected by an elongate shaft with a central lumen. The proximal end is to be held and manipulated by an operator (e.g., a surgeon) to navigate the distal end to the tympanic cavity of a person via the external ear canal and through the tympanic membrane. The distal end of the device is intended to effect ablation and as such comprises an ablation effector component.
[0049] In another embodiment, in addition to the ablation effector, the distal end of the device may also include an image capture component (e.g., a miniature or subminiature CMOS imaging sensor), and / or an illumination component (e.g., a plastic or glass fiber in communication with a light source or a light emitting diode or LED) facilitating direct visualization of the middle ear anatomy. The image captured by the image capture component (e.g., the component’s output) is displayed on a monitor or other display device (e.g., smartphone or tablet) via an image processing component that is either housed within the proximal end, physically connected through a communication cable or the like to the proximal end, or is alternatively in wireless communication (e.g., using Bluetooth or WIFI) with the proximal end of the device. The proximal end may be used to manipulate and control the device during the ablation procedure.
[0050] In another embodiment, in addition to the ablation effector, image capture and illumination components, the distal end comprises a working channel to advance surgical tools such as an otology (ear) pick to the surgical site, allowing additional operations to be conducted under endoscopic visualization. The proximal end of said working channel can beoptionally attached to a vacuum source to aspirate excess fluids and the like from the surgical field to improve visualization.
[0051] In another embodiment, in addition to the ablation effector, image capture and illumination components, the distal end includes and incorporates a cutting component that can be used to create an incision in the tympanic membrane providing access to the tympanic cavity.
[0052] In one embodiment of the device where the device includes image capture and / or illumination components, the ablation effector is arranged so it can slide axially in relation to the other components of the distal end. For example, in one configuration, the ablation component is arranged in parallel and in line with the image capture and the illumination components during the navigation of the distal end to the target site. Once the device reaches the proximity of the target tissue, the ablation component is slid forward (e.g., distally towards the promontory in the middle ear space) in relation to the other components of the distal end, placing the ablation effector in the field of view (e.g., in front of) the image capture component allowing the operator to monitor, observe and control the ablation procedure.
[0053] In one example, the mechanism to control the axial sliding movement of the ablation effector is housed within the proximal end of the device. Therefore, the operator can control the movements of the ablation component from the proximal end of the device. In another example, the mechanism to control the axial sliding movement of the ablation effector is housed within an external structure where the external structure is in electrical and / or wireless communication with the proximal end of the device.
[0054] In one embodiment, the device’ s entire elongate shaft is substantially straight. In another embodiment, a portion of the distal end of the elongate shaft is bent at an angle of about 0- 120 degrees in relation to a portion of the elongate shaft. Positioning the distal end and therefore the ablation effector at an angle to a portion of the elongate shaft can facilitate ablation of a greater surface area of target tissue or provide access to tissues that are not directly in line with the entry point at the tympanic membrane. In one example, the distal portion of elongate shaft can be prefabricated to have a bend or angle in relation to the rest of the elongate shaft or alternatively the distal portion of the elongate shaft may include a malleable or bendable portion and / or connection that can be manipulated to the desired bendangle by the operator. In yet another embodiment, the connection between the distal end and the shaft may be rendered steerable (using methods commonly known in the art) to allow the operator to intra-procedurally control the bend angle of distal end of the elongate shaft relative to the rest of the elongate shaft as needed.
[0055] In one embodiment of the device, some or all components of the distal end of the device are designed to have a collapsed and an expanded configuration. During navigation of the distal end of the device through the external ear canal to the tympanic cavity, parts or all of the distal end may be in a collapsed state facilitating navigation. Once inside the tympanic cavity, part or all of the distal end can be expanded to increase the contact area between the distal end and the target tissue. Once the ablation procedure is completed, all or part of the distal end that has been expanded can return to the collapsed state to ease and facilitate atraumatic navigation of the device out of the tympanic cavity. In one example of this embodiment, the ablation effector is the only component that can change from a collapsed to an expanded state.
[0056] In another embodiment where the distal end includes image capture and / or illumination components, once the distal end of the device reaches the tympanic cavity, the ablation component is slid axially forward in relation to other components of the distal end and is transformed from a collapsed state to an expanded state. Upon the completion of the procedure, the ablation component is collapsed, slid backward to be back in line with other components of the distal end, and the distal end is navigated out of the tympanic cavity.
[0057] In one embodiment of the device, the ablation effector is a cryosurgical device or a cryoprobe operating under the Joule-Thompson effect to cause extreme cold temperatures capable of effecting nerve ablation. In this example, the cryosurgical probe or cryoprobe is provisioned with a gas conduit for delivering pressurized cryogenic gas or liquid from a gas or liquid source to the probe head and another, preferably coaxial, conduit for removing the excess coolant gas away from the probe head. The cryogenic material may be stored in a cartridge, capsule or other suitable container, sized to be housed within the proximal end of the device or separately from the device with the gas or liquid ported to the device via a tube in fluid communication with the cryoprobe lumen. The operator can control the ablation procedure either using a switch or other control mechanism on or within the proximal end or alternatively using a foot pedal or other means of controlling the ablation, located away from the proximal end.
[0058] In another embodiment where the distal end includes image capture and / or illumination components, the cryo robe may be insulated to be thermally isolated from the rest of the components of the device to prevent or reduce the potential for thermal damage to such components and to limit or prevent collateral damage to non-target tissues (e.g. the tympanic membrane). In yet another embodiment, a heating element can be incorporated within the device at the proximal end, distal end, and / or along the elongate member to maintain the temperature of the image capture and / or illumination components at desirable operating temperatures. Said heating element may also be beneficial in preventing or reducing collateral damage to non-target tissues (e.g. the tympanic membrane or to walls of the external ear canal) by modulating or reducing cold temperatures by the cryogenic material flowing within the device or along the elongate member. The heating elements in this embodiment may comprise thermofoil heaters and flex circuits. The cry oprobe may optionally be slidably disposed in relation to other components of the distal end allowing it to be extended towards the target tissue once the device has passed through the incision in the tympanic membrane.
[0059] In one example of this embodiment, the cryoprobe operates on the basis of the Joules-Thomson effect and is in form of an expandable balloon. Once the probe is in proximity of target tissue, the coolant gas or liquid used to cause extreme cold temperatures can be used to expand the balloon. Upon the completion of the procedure, the flow of the cryogenic gas or liquid is stopped resulting in the balloon deflating to substantially its original size and returning to environmental temperature. The cryoprobe (balloon) can then be navigated to a subsequent ablation target in the middle ear or alternatively retracted out of the tympanic cavity.
[0060] In one embodiment, the ablation effector is a cryoprobe that uses nitrous oxide liquid / gas to produce the cold temperature. In another embodiment, the cryoprobe uses carbon dioxide. In yet another embodiment the cryoprobe uses liquid nitrogen. In one embodiment, the cryoprobe uses chlorofluorocarbon, hydrochlorofluorocarbon, hydrofluorocarbon or any mixtures thereof as cryogenic material.
[0061] In another embodiment, the cryoprobe uses principles other than the Joules- Thompson effect to produce cold (cryogenic) temperature conditions.
[0062] In another embodiment of the device, the ablation effector is a cryoprobe that sprays cryogenic material directly onto the target tissue in the middle ear space to effect ablation.
[0063] In one embodiment of the device of the current invention, the ablation effector uses heat to effect ablation. Different energy modalities such as bipolar, radiofrequency, pulsed radiofrequency, ultrasonic and microwave can be used to heat the target tissue and effect ablation.
[0064] In one embodiment, the ablation component delivers liquid or semi-liquid chemicals onto the target tissue to effect ablation. Examples of such chemicals include, but are not limited to ethanol, phenol, formulations or combinations thereof.
[0065] In another embodiment, the ablation component delivers liquid or semi-liquid therapeutic agents to induce ablation. Examples of such agents includes, but are not limited to capsaicin and its analogues (e.g. Zucapsaicin, ALGRX-4975, Nonivamide,Resinif eratoxin, or combinations thereof), therapeutic agents acting on TRP channels such as TRPA1, TRPM8, or TRPV1, CGRP or substance P agonist or antagonist, sympatholytic agents such as alpha- and beta-adrenergic receptor antagonists (e.g., alpha and beta blockers), as well as centrally acting agents such as clonidine, guanabenz, methyldopa, minoxidil, and reserpine.
[0066] Methods of using the devices described may include using the devices to ablate a nerve within the tympanic cavity to treat diseases related to dysfunction of the said nerve. According to one method, the surgeon consults with the patient to ascertain that the patient is a candidate for the current procedure. After applying appropriate anesthesia, the surgeon uses a surgical tool or alternatively the devices described herein to create an incision in the tympanic membrane of the patient. The distal end of the device is then navigated through the external ear canal under direct visualization to enter the tympanic cavity through the incision in the tympanic membrane. The visualization component of the device is used to safely navigate the anatomy and to visually identify the target nerve or nerves once positioned within the tympanic cavity. The ablation effector of the distal end of the device is positioned at the desired location on the nerve trajectory followed by ablation of the said nerve or nerves. For this step, the ablation effector is positioned in direct contact with all or a portion of the nerve or nerves targeted for ablation under direct endoscopic visualization.Once the desired amount of the target nerve or nerves is / are ablated, the ablation procedure is stopped. It is envisioned that the ablation procedure may be optionally repeated multiple times at the same or different locations along the nerve or its branches to achieve the desired therapeutic effect. Once the ablation is completed, the device is navigated (e.g., retracted) out of the tympanic cavity through the incision in the tympanic membrane and out of the external ear canal under direct visualization. Post operatively, the external ear canal may be packed with appropriate packing material to accelerate healing of the incision in the tympanic membrane.
[0067] In an alternative method of using the device, in lieu of creating an incision in the tympanic membrane to gain access to the tympanic cavity, the surgeon uses a surgical tool to create an incision in the external ear canal and elevates a portion of the tympanic membrane in the form of a tympanomeatal flap. The distal end of the device is then navigated through the external ear canal under direct visualization to enter the tympanic cavity to perform the ablation procedure. Upon completion of ablation, the device is navigated out of the tympanic cavity and external ear canal. The tympanomeatal flap is then retuned and secured, sutured or otherwise attached to its original position as surgically practicable. In another embodiment facial recess procedure is used to access tympanic cavity.
[0068] In yet another method of using the device, the ablation device does not include or incorporate visualization components (e.g., image capture and / or illumination components). In this instance, after confirming the patient to be a candidate for the procedure and after applying appropriate anesthesia, the surgeon uses a surgical tool to either create an incision in the tympanic membrane or alternatively create an incision in the patient’s external ear canal and raise a portion of the tympanic membrane in form of a flap or use a facial recess procedure. A visualization tool e.g. a traditional rigid or flexible endoscope or a microscope is used to perform the procedure. The distal end of the device is then navigated through the external ear canal adjacent to said visualization tool to enter the tympanic cavity under direct visualization. Upon completion of the ablation procedure the treatment device and the visualization tool are navigated out of the patient’s ear either in sequence or together.
[0069] In yet another method for treating dysfunctions or diseases in a patient, the method may generally comprise creating access to a tympanic cavity of a patient, introducing a treatment device into the tympanic cavity of the patient, the treatment devicehaving a proximal end, a distal end, an elongate shaft therebetween, and an ablation effector disposed at or near the distal end of the device, advancing the distal end of the device under direct visualization into proximity of a nerve or nerves within the tympanic cavity, and ablating the nerve or nerves using the ablation effector to reduce at least one symptom of nerve dysfunction or disease.
[0070] One embodiment of a cryoprobe system may generally comprise an elongate probe connected at a proximal end to a handle and having an ablation effector at a distal end, wherein the ablation effector defines a lumen such that the ablation effector is configured to conduct cryogenic energy when a cryogen Hows within the lumen, a sheath slidably positioned over the elongate probe and having a sheath tip which is configured to deflect relative to the sheath, wherein the sheath tip transitions the ablation effector into an arcuate configuration which conforms to an underlying tissue region when the sheath is retracted, an exhaust line fluidly coupled to the elongate probe, and a reservoir holder fluidly coupled to the exhaust line and configured to retain a removable reservoir of cryogen which is in fluid communication with the lumen defined by the ablation effector.
[0071] One embodiment of a method of treating a tissue region within a tympanic cavity may generally comprise advancing an elongate probe having an ablation effector at a distal end into proximity of a nerve trajectory within a tympanic cavity, retracting a sheath having a sheath tip slidably positioned over the elongate probe to deploy the ablation effector, conforming the ablation effector against at least a portion of the nerve trajectory such that the sheath tip deflects relative to the sheath and transitions the ablation effector into an arcuate configuration against the portion of the nerve trajectory, and introducing a cryogen into a lumen defined through the ablation effector such that the ablation effector conducts cryogenic energy and ablates the portion of the nerve trajectory.BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1A shows the schematic side view of the structures of an ear.
[0073] Figure IB is the schematic of structures, including the nerves, within the tympanic cavity (middle ear) of an ear.
[0074] Figure 2 A shows the schematic of the device of the current invention accessing the tympanic cavity through the external ear canal and tympanic membrane.
[0075] Figure 2B shows the distal end of the device of the current invention advanced through the incision in the tympanic membrane and positioned within the tympanic cavity in proximity with or in direct contact with some or all of the nerve(s) targeted for ablation.
[0076] Figure 3A shows a schematic cross-sectional view of the distal end segment of the device of the invention along with its components.
[0077] Figure 3B-3D shows schematics of various configurations of the ablation effector component of the distal end segment of the device in relation to other components of the device.
[0078] Figures 4A-4C shows various configurations of the device depicting the distal end in varying configuration relative to the elongate shaft. Figure 4A shows the distal end of the device in line with the elongate shaft. Figure 4B shows the distal end of the device sitting an angle in relation to the elongate shaft. Figure 4C shows the device’s elongate shaft having a steerable section at its junction with the distal end allowing for in-situ adjustment of the angle of the distal end relative to the elongate shaft.
[0079] Figure 5A depicts a configuration of the device and systems of the current invention wherein a gas / liquid cartridge, a control mechanism to axially slide the distal end and / or its ablation component, and an image processing component are located within the proximal end of the device (shown in a device handle) which is in turn connected to an external light source and display device.
[0080] Figure 5B depicts a configuration of the device and systems of the current invention wherein where only the control mechanism to axially slide the distal end and / or its ablation component are housed within the proximal end of the device while other components are housed external to the proximal end (or device handle).
[0081] Figure 6A depicts a cryoprobe system comprising a cryoprobe connected to a detachable, remote canister holder.
[0082] Figure 6B depicts a side plan view of a cryoprobe device component of a system of the invention with the valve switch in the undepressed position wherein refrigerant gas or liquid is not flowing into the distal segment of the device.
[0083] Figure 6C depicts the internal components of the cryoprobe device provided in Figure 6B.
[0084] Figure 6D provides a cross sectional view (Section 6D-6D) of the cryoprobe device provided in Figure 6B.
[0085] Figure 6E provides a closeup depiction of the cryoprobe valve assembly referenced in Detail A of Figure 6D.
[0086] Figure 6F depicts a side plan view of a cryoprobe device component of a system of the invention with the valve switch in the depressed position wherein gas is flowing into the distal segment of the device.
[0087] Figure 6G provides a cross sectional view (Section 6G-6G) of the cryoprobe device provided in Figure 6F.
[0088] Figure 6H provides a closeup depiction of the cryoprobe valve assembly referenced in Detail B of Figure 6G.
[0089] Figure 61 provides a closeup depiction of the distal segment of cry oprobe 601 referenced in Detail B of Figure 6D with the sliding sheath component of the device fully retracted exposing the flexible probe.
[0090] Figure 6J provides an exploded isometric view of a canister holder component of the cryoprobe system along with a cryogenic gas canister component and the proximal segment of the cryoprobe device component of Figure 6A.
[0091] Figures 6K and 6L depict front and side views, respectively, of the components provided in Figure 6J after the canister adapter component on the proximal segment of the cry oprobe and the cryogenic gas canister component have been loaded and secured within the canister holder.
[0092] Figure 6M provides a cross sectional view of the canister holder referenced in Section 6M-6M of Figure 6K.
[0093] Figure 6N provides a closeup depiction of canister adapter (Detail D) referenced in Figure 6M engaged with the cryogenic gas canister secured within the canister holder.
[0094] Figure 7A depicts a cryoprobe system comprising a cryoprobe connected to a remote, integrated canister holder.
[0095] Figure 7B provides an exploded plan view of the remote, integrated canister holder of Figure 7 and its related components.
[0096] Figure 7C is a close-up, cross sectional view of the remote, integrated canister holder of Figure 7A and its related components after the gas canister has been activated.
[0097] Figure 8A depicts a cryogenic probe component of the system of the invention with the slidable sheath fully advanced to the probe tip with said tip engaged against tissue targeted for cryoablation treatment.
[0098] Figure 8B depicts a cryogenic probe component of the system of the invention with the slidable sheath partially retracted to expose a portion of the flexible probe with the exposed segment of the flexible probe engaged against tissue targeted for cryoablation treatment.
[0099] Figure 8C depicts a cryogenic probe component of the system of the invention with the slidable sheath fully retracted to completely expose the flexible probe with the completely exposed segment of the flexible probe engaged against tissue targeted for cryoablation treatment.
[0100] Figure 9 outlines a step-by-step method to use the devices described in this invention to treat diseases via neuroablation in the tympanic cavity.
[0101] Figure 10 outlines a step-by-step method to use cryoprobe devices and systems of the invention to treat diseases via neuroablation in the tympanic cavity.DETAILED DESCRIPTION OF THE INVENTION
[0102] In order to provide clarity regarding the relevant anatomical structures of the ear, Figure 1A shows the auricle 100, external auditory canal 101, tympanic membrane 102 and the promontory of the tympanic cavity 103. Figure IB shows a simplified close-up picture of the tympanic cavity with tympanic membrane 102, promontory 103, tympanic nerve, a branch of the glossopharyngeal nerve, 104, tympanic plexus, combination of tympanic nerve with sympathetic fibers from the internal carotid nerve, 105, lesser petrosal nerve 106 and chorda tympani 107 a branch of the facial nerve 108.
[0103] Figure 2A shows a schematic of the device of the current invention 200 comprising proximal end 200A, elongate shaft 200B and distal end 200C. The proximal end 200A is used by an operator to navigate the distal end through auricle 201, across external ear canal 202, through an incision in tympanic membrane 203 to enter tympanic cavity 204 in proximity to promontory 205. The length of elongate shaft 200B is designed so that proximal end 200A (e.g., the device handle) remains outside of the patient’s ear while distal end 200C is positioned in proximity to structures within tympanic cavity 204. The length of elongate shaft 200B is about 5-30 cm, or preferably within the range of 10cm to 20cm.Figure 2B shows a close-up of tympanic cavity 204, where distal end 200C of device 200 has been navigated through incision 206 in the tympanic membrane 203. Incision 206 can be created using standard surgical technique and instruments prior to inserting device 200 into the patient’s ear or it can be created using device 200 on its way to tympanic cavity 204. The diameter of incision 206 is about 0.5mm to 3 mm, or preferably between 1mm to 2.5mm. Once inside tympanic cavity 204, distal end 200C is used to ablate targeted nerve tissues including, but not limited to the tympanic nerve 207, tympanic plexus 208, lesser petrosal nerve 209 or chorda tympani 210.
[0104] In one embodiment, in addition to ablating a nerve or nerves, device 200 is configured to illuminate and visualize the inside of tympanic cavity 204 to identify the targeted nerve or nerves and perform the procedure.
[0105] In yet another embodiment (not shown), instead of incision 206 of the tympanic membrane 203 to access the tympanic cavity 204, an incision can be made in external ear canal 202 in proximity to the tympanic membrane 203 in order to elevate a portion of tympanic membrane 203 in form of a flap to provide distal end 200C access to tympanic cavity 203.
[0106] Figure 3A shows the cross-section of distal end 300 of the device of the current invention comprising lumen 301, ablation effector 302, optional image capture component 303, optional illumination component 304, optional working channel 305, and optional cutting component 306. The diameter of distal end 300 is such that it can navigate through a small incision in the tympanic membrane if desired and in general operate within the confines of the tympanic cavity space (not shown) and is expected to be 1mm to 3mm or preferably between 1mm to 2.5mm in diameter.
[0107] Optional cutting component 306 can be used to create the desired tympanic membrane incision 202 (described previously in Figure 2B). In one embodiment, optional cutting component 306 is designed to slide back and forth axially along all or part of the elongate shaft of the device (not shown). In another embodiment, optional cutting component 306 is designed to rotate around the perimeter of distal end 300. In yet another embodiment, optional cutting component 306 is designed to rotate around the perimeter of distal end 300 and slide along elongate shaft of the device (not shown). In one example of this configuration, initially optional cutting component 306 is positioned in the proximal section of elongate shaft of the device (not shown). Once distal end 300 is navigated through the external ear canal and is positioned in the proximity of tympanic membrane (not shown), cutting component 306 is slid forward towards distal end 300 so that it comes in contact with the tympanic membrane (not shown). Cutting component 306 then rotates along the perimeter of distal end 300 while in contact with the tympanic membrane to create an incision. Once the desired incision is created, cutting component 306 is slid backward (e.g. retracted) towards the proximal end of the device (not shown) placing its cutting surface along the elongate shaft in a position that facilitates safe delivery of the device as required into the tympanic cavity.
[0108] Figure 3B shows the side view of distal end 300 comprising ablation effector 302, optional image capture component 303, optional illumination component 304, optional working channel 305 and optional cutting component 306. In one embodiment of this invention, ablation effector 302 is in line and on the same plane as other components of distal end 300.
[0109] In one embodiment of the current invention, ablation effector 302 is a cryoprobe using Joule’s Thompson (JT) effect to create temperatures between, e.g., -20°C to -100°C to effect nerve ablation. In this embodiment, a compressed refrigerant gas or liquid is ported through the cryoprobe via a small internal lumen to the proximity of the tip of the cryoprobe at which point the refrigerant gas or liquid exits the internal smaller lumen to enter a coaxial larger lumen (not shown). The refrigerant gas or liquid may be contained within a reservoir (not shown) located within the proximal end or externally of the proximal end and in fluid communication with ablation effector 302 through the elongate shaft 200B (shown in Figure 2A). The expansion of the refrigerant gas or liquid during transition from the smallerlumen to the larger lumen generates extremely low (cryogenic) temperatures at the tip of the cryoprobe.
[0110] In one embodiment of this invention, ablation effector 302 is a cryoprobe that uses compressed nitrous oxide gas or liquid to create the extremely low temperatures. In another embodiment, the refrigerant gas or liquid may comprise carbon dioxide as the refrigerant and in yet another embodiment, the refrigerant may comprise a chlorofluorocarbon, hydrochlorofluorocarbon, hydrofluorocarbon or any mixtures thereof to produce the extremely low temperatures.
[0111] In one embodiment, ablation effector 302 is a cryoprobe that uses liquid nitrogen to produce extreme low temperatures. In yet another embodiment, ablation effector 302 uses other methods than JT effect to produce the extremely low temperatures necessary for tissue ablation.
[0112] In another embodiment, ablation effector 302 uses heat to ablate tissue. The heat for ablation can be produced by various energy modalities including, but not limited to bipolar radiofrequency, pulsed radiofrequency, microwave or ultrasonic energy.
[0113] In one embodiment, ablation effector 302 delivers liquid or semi-liquid chemicals unto the target tissue to effect ablation. Examples of such chemicals include ethanol, phenol, or formulations or combinations thereof.
[0114] In another embodiment, ablation effector 302 delivers liquid or semi-liquid therapeutic agents to induce ablation. Examples of such agents include, but are not limited to capsaicin and its analogues (e.g. Zucapsaicin, ALGRX-4975, Nonivamide, Resiniferatoxin, or combinations thereof), therapeutic agents acting on TRP channels such as TRPA1, TRPM8, or TRPV1, CGRP or substance P agonist or antagonist, sympatholytic agents such as alpha- and beta-adrenergic receptor antagonists (e.g., alpha and beta blockers), or centrally acting agents such as clonidine, guanabenz, methyldopa, minoxidil, and reserpine.
[0115] In one embodiment, the diameter of ablation effector 302 is about 0.5mm to 3mm. In a preferred embodiment, the diameter of ablation effector 302 is between 0.5mm to 2mm.
[0116] In one embodiment, optional image capture 303 is a miniature or subminiature CMOS and optional illumination component 304 is fiber optic bundle connected to an external light source (not shown). In another embodiment, optional illumination component 304 is a light emitting diode (LED) or alternatively a laser light source. The CMOS would be positioned proximal to a glass or plastic lens (also not shown) used to provide the desired focal length and field of view within the tympanic cavity.
[0117] Figure 3C shows the side view of distal end 300 comprising ablation effector 302’, optional image capture component 303, optional illumination component 304, and optional working channel 305, where ablation effector 302’ is positioned distal (slide forward axially) relative to the other components shown at distal end 300. This configuration allows for better visualization of the ablation procedure occurring at the tip of ablation effector 302’ by positioning it in the field of view (e.g., in front of or distal to) the image capture component 303.
[0118] In one embodiment, ablation effector 302’ is positioned about 1mm to 25mm distal to other components of distal end 300. In another embodiment, the distance between the most distal tip of ablation effector 302’ relative to the other components of distal end 300 is between 1mm to 10mm or even more preferably between 1mm to 5mm.
[0119] In one embodiment, the ablation effector 302’ is designed to slide axially back and forth relative to other components of distal end 300. During navigation to the tympanic cavity, ablation effector 302’ is in line with other components of distal end 300. Once within the tympanic cavity and after the nerve tissue targeted for ablation is visually identified, ablation effector 302 (as depicted in Figure 3B) is slid forward (distally) relative to other components of distal end 300 to the position of ablation effector 302’ (as depicted in Figure 3C) placing the distal most tip of the ablation effector 302 in front of or distally and within the field of view and focal length of image capture component 303. Upon completion of the procedure and prior to navigating out of the tympanic cavity, ablation effector 302’ is slid backward or retracted axially to position of ablation effector 302 (as depicted in Figure 3B) in line with other components of distal end 300 facilitating navigation of the device out of the patient’ s ear.
[0120] Figure 3D shows a side view of distal end 300 comprising ablation effector 302”, image capture component 303, illumination component 304, and optional workingchannel 305. In this configuration, ablation effector 302” has an expandable tip. During navigation to the target tissue, ablation effector 302” is in a collapsed state to facilitate navigation (similar to ablation effector 302’ depicted in Figure 3C). Once ablation effector 302” is in proximity to the targeted tissue or nerve(s), it can change form a collapsed state to an expanded state to facilitate ablation of larger surface area of tissue possibly also improving conformity of ablation effector 302” to uneven tissue surface morphologies. Upon completion of the ablation procedure and prior to navigation (e.g., retraction) out of a patient’s ear, ablation effector 302” is returned to the collapsed state (similar to ablation effector 302’ as depicted in Figure 3C) to ease retraction from the anatomy and to reduce unintended trauma or tissue damage during retraction.
[0121] It is contemplated that ablation effector 302” can also slide axially relative to other components of distal end 300 in addition to assuming collapsed and expanded states. For example, during navigation to the target tissue, ablation effector 302” can be arranged in line with other components of distal end 300 (in a configuration similar to ablation effector 302 depicted in Figure 3B). Once effector 302’ ’ is in proximity of targeted tissue, it can be slid forward (e.g., distally or axially) relative to other components of distal end 300 (in a configuration similar to ablation effector 302’ depicted in Figure 3C) and change from collapsed state to expanded state. Upon completion of the ablation procedure, ablation effector 302” can then revert back to its original collapsed state and slide backward axially to line it up with other components of distal end 300 prior to navigation (e.g., retraction) out of the patient’s ear.
[0122] In one embodiment the ablation effector 302” is a cry oprobe using the Joule’s Thompson (JT) effect to create temperatures between -20°C to -100°C to effect ablation and the expandable portion of ablation effector 302” is a balloon. In this configuration the refrigerant gas used to cause JT effect is also used to simultaneously expand the balloon. Upon the completion of the ablation procedure, the flow of the refrigerant gas is stopped bringing the temperature of ablation effector 302” back to environmental temperatures at the same time causing deflation of the balloon.
[0123] In another embodiment, the expandable portion of ablation effector 302” is a structure can be fabricated from thermally conductive materials capable of assuming a collapsed and an expanded state. In one embodiment, the thermally conductive material is ametal (e.g. Nitinol) which can be expanded and collapsed based on the shape-memory properties of the material.
[0124] Figure 4 A depicts the schematic of device 400 of this invention with proximal end 400A, elongate shaft 400B and distal tip 400C. In this embodiment distal tip 400C is in line (on axis with) and in a straight configuration relative to elongate shaft 400B. Figure 4B depicts device 400 where distal end 400C sits at an angle relative to elongate shaft 400B. It is contemplated that the angle between distal end 400C and elongate shaft 400B is between, e.g., 0 degrees to 120 degrees. In a preferred embodiment, this angle is between, e.g., 0 degrees to 90 degrees. The contemplated angle is designed to facilitate and ease access to nerve tissues situated at various angles relative to the entry point (e.g., the incision point in the tympanic membrane) of device 400 into tympanic cavity.
[0125] In one embodiment of the current invention, distal tip 400C includes a specific bend angle at distal end 400C. In another embodiment, elongate shaft 400B is composed of a malleable material or construction that allows intraprocedural adjustment or tailoring or bending of distal end 400C by the operator in accordance with the specific geometric or anatomic requirements of a specific patient’s ear.
[0126] Figure 4C depicts a schematic of device 400 wherein elongate shaft 400B has a steerable portion 401, the movement of which can be controlled by the operator. In this embodiment, the bend angle between distal end 400C relative to elongate shaft 400B can be adjusted in-situ (intraprocedurally) as desired by the operator.
[0127] Figure 5A depicts the schematic of device 500 comprising proximal end 500A, elongate shaft 500B and distal end 500C, where distal end 500C comprises a cry oprobe as ablation effector (not shown) and a working channel component (not shown). Proximal end 500A houses lumen 501 that can optionally be connected to a vacuum source using tubing 502 or can be used to pass surgical tools from proximal end 500A through elongate shaft 500B to the surgical site. Lumen 501 is connected to the working channel of the device (not shown). Proximal end 500A also houses compressed liquid or gas refrigerant cartridge 503 which is in fluid communication with distal tip 500C. Control mechanism 504 is also placed within proximal end 500A. Control mechanism 504 allows the operator to control the movement of the ablation effector, adjust the bend angle of distal tip 500C relative to elongate shaft 500B, and / or control the movements of the cutting component ofdistal end 500C (not shown). Image processing component 505 is in wireless communication with the image capture device of distal end 500C (not shown) and in electronic communication with image display device 507 through cable 506. Proximal end 500A is connected to external light source 508 through cable 509. Cable 509 is in communication with the illumination component of distal end 500C (not shown).
[0128] As middle ear surgery involves operating in small spaces and around delicate / sensitive anatomical structures, and in order to provide the operator with better control and more precise manipulation of the device of the current invention, it would be preferrable to reduce the weight and volume of the proximal end 500A of the device. Figure 5B depicts schematics of device 500 with proximal end 500A, elongate shaft 500B and distal end 500C. Proximal end 500A houses lumen 500A that can be optionally connected to a vacuum source through tube 502 or be used as a general-purpose working channel. It also houses control mechanism 504 that can control the movement and operation of the ablation effector (not shown), distal end 500C in relation to elongate shaft 500B, and / or the cutting component (not shown). Compressed liquid or gas refrigerant cartridge 503 and image processing component 506 are housed within external structure 508 along with the illumination light source. Cartridge 503 is in liquid communication with proximal end 500A and distal end 500C through tube 510. Image processing component 506 can be in wireless communication with image capture device component of distal end 500C (not shown) and electronically connected to image display device 507 using cable 505’in the form of, e.g., an HDMI or USB connector or the like well-known in the art. Proximal end 500 A is connected to external light source 508 through cable 509. Cable 509 is in communication with the illumination component of distal end 500C (not shown).
[0129] Figure 6A depicts an overview of a cryoprobe system 600 embodiments of the generally include a cryoprobe 601 connected to detachable, remote canister holder 610. Cryoprobe 601 is a handheld surgical instrument that can be used for cryoablation treatment. The cry oprobe 601 comprises an ablation effector (e.g., probe tip 602 and flexible probe 603), a sliding sheath 604, a handle 605 incorporating valve switch 606 and actuator switch 607, and an elongate exhaust line 608 terminating with a canister adapter 609. The system of Figure 6A also includes a canister holder 610 comprising an optional hanger 611, canister holder lid 612, lock 613, and canister holder body 614 attached to and in fluid communication with cryoprobe 601 via canister adapter 609. In this embodiment, a canister(not shown) containing a cryogen (e.g., pressurized nitrous oxide gas or liquid) is secured within canister housing 610 with said cryogen in fluid communication with cryoprobe 601. Probe tip 602 and flexible probe 603 are at the working end of cry oprobe 60 land are both capable of transmitting cryogenic energy from the device to adjacent tissues in contact with probe tip 602 and flexible probe 603 enabling cryoablation of said tissues. Probe tip 602 is preferably an atraumatic component capable of conducting cryogenic energy. Probe tip 602 has proximal and distal end with a lumen therethrough, the distal most end is closed and preferably has a bullet shape or otherwise atraumatic geometry. Flexible probe 603 comprises an elongate member with proximal and distal end with a lumen therethrough preferably including elements within its lumen (not shown) to maintain luminal integrity when flexed. In doing so, the lumen of flexible probe 603 shall be capable of conducting cryogenic energy when a cryogen flows within it when said probe is straight or flexed (e.g., in contact with a tissue targeted for cryoablation treatment). Furthermore, flexible probe 603 is capable of conforming to tissues targeted for cryoablation treatment thereby increasing the surface area of contact of flexible probe 603 with said tissues allowing for increased transmission of cryogenic energy to larger tissue regions compared to just using probe tip 602. Probe tip 602 and flexible probe 603 are preferably of sufficiently low profile to allow access to target tissues in various body lumens, cavities, etc. targeted for cryoablation treatment. Sliding sheath 604 is an elongate member with a proximal and distal end with a lumen therethrough and coaxially oriented and slidably disposed along flexible probe 603 such that manual advancement of actuator switch 607 covers or sheathes flexible probe 603 and manual retraction of actuator switch 607 uncovers or unsheathes flexible probe 603. As such, the surgical operator is conferred the flexibility to tailor the cryoablation treatment area for a given patient’s needs and anatomy ranging from a focal point cryoablation treatment using only probe tip 602 when sliding sheath 604 is fully advanced to a larger cryoablation treatment area when sliding sheath 604 is fully retracted, thus adjusting the available length of flexible probe 603 for cryoablation treatment Sliding sheath 604 may be rigid or flexible depending on the clinical, procedural and / or anatomical requirements. Handle 605 also incorporates valve switch 606 which can be depressed to enable the flow of cryogenic gas to probe tip 602 and flexible probe 603, through inner gas line 632 coaxially disposed within the lumen of the flexible probe 603 and probe tip 602 (not shown), when a surgical operator is ready to apply cryogenic energy to target tissues. Valve switch 606 is connected to a spring-loaded valve assembly (not shown) which returns valve switch 606 to its normalposition wherein gas flow to probe tip 602 and flexible probe 603 is ceased when the surgical operator stops pressing valve switch 606.
[0130] Exhaust line 608 extends from the proximal end of handle 605. Exhaust line608 comprises an elongate member with a proximal and distal end and a lumen therethrough. The lumen of exhaust line 608 coaxially houses a flexible gas line (not shown). Exhaust line 608 provides a pathway to dissipate refrigerant gas or liquid used in cryoprobe 601 to the atmosphere via exhaust ports 615 located at the proximal end of exhaust line 608. Exhaust port 615 may comprise one or more side holes provided in the wall of exhaust line 608. Exhaust line 608 terminates with canister adapter 609 which may be bonded or otherwise attached to the proximal most end of exhaust line 608. Canister adapter 609 is designed to be adapted with and secured at the distal end of canister holder 610. Tn addition, canister adapter 609 includes desiccant material(s) and filter(s) (not shown) to ensure refrigerant gas or liquid delivered through it is clean and dry. Canister holder 610 comprises a rigid housing with a canister holder body 614 that includes an inner cavity which can accept placement of a liquid or gas cryogen canister (not shown). As noted previously, the distal end of canister holder 610 is designed to adapt or mate with canister adapter 609 thereby allowing fluid communication with said canister adapter 609. Canister holder 610 also includes canister holder lid 612 at its proximal end which can be used to hold a cryogen canister (not shown) within the cavity of canister holder body 614 and secured via lock 613 since the canister’s content is under high pressure. Optionally, canister holder 610 may incorporate hanger 61 1 as shown in Figure 6A which can be used to hang canister holder 610 in a vertical orientation on an IV pole or the like. In an alternative embodiment, hanger 611 may be replaced with alternative means known in the art such as a clamp or a tape or the like to secure canister holder 610 in a vertical orientation to a bedside, a table or the like. In general, the remotely located canister holder 610 enables cryoprobe 601 to be a lighter, lower mass surgical instrument that can be more easily manipulated and precisely controlled by a surgical operator when doing delicate procedures.
[11131] A pressurized cryogen canister (not shown) might contain both the gas and liquid forms of the cryogen. Canister holder 610 and hanger 611 hold the pressurized cryogen canister in a vertical upside-down position, allowing the liquid form to flow to cryoprobe handle 605 regardless of the angle at which it is held. The flow of liquid cryogen versus its gas form allows achievement of lower temperatures at probe tip 602 and flexibleprobe 603. The angle at which cry oprobe handle 605 is held is dependent on the position of the patient and the treatment site.
[0132] A flexible gas line (not shown) is in fluid communication with the cryogenic canister source carrying the cryogenic gas or liquid through the canister adaptor 609 and its components (not shown), disposed within exhaust line 608 and handle 605, bringing the cryogenic gas to the effector at the distal end of cry oprobe 601 (e.g., to flexible probe 603 and probe tip 602), and releasing the cryogenic liquid or gas within the lumen of flexible probe 603 and probe tip 602. Having flexible gas line (not shown) disposed within exhaust line 608 allows for outgoing exhaust cryogen to cool the incoming cryogen gas thereby increasing the efficiency of cry oprobe 601 by further reducing the temperature at probe tip 602 and flexible probe 603. The expansion of the cryogenic gas or liquid within the lumen of flexible probe 603 and probe tip 602 causes a drop in temperature. The flow of the cryogenic gas or liquid to the distal end of cry oprobe 601 can be controlled by manipulation of valve switch 606 by the surgical operator as previously noted. When valve switch 606 is depressed, the cryogen travels distally resulting in temperature drop at flexible probe 603 and probe tip 602 and when valve switch 606 is released, the flow of the cryogenic gas within the flexible gas line (not shown) and the ablation is thereby terminated.
[0133] Figures 6B and 6F provide more detailed illustrations of the cryoprobe system600 described in Figure 6A. Specifically, Figure 6B depicts a side plan view of cryoprobe601 with valve switch 606 positioned in a undepressed position on handle 605 such that refrigerant gas or liquid communicated from the canister housing (not shown) is unable to flow into the distal segment of cryoprobe 601. Handle 605 may include a two-part clamshell handle housing 619 fastened together with screws 616. The two-part clamshell handle housing 619 may be fabricated using standard manufacturing methods known in the art such as injection molding, machining or 3-D printing and produced using polymeric or metallic materials know in the art including, but not limited to polycarbonate, acetal, nylon, stainless steel, aluminum and the like.
[0134] Figure 6B also illustrates slidable actuator switch 607 positioned such that sliding sheath 604 is fully retracted exposing the entire length of flexible probe 603 that can be available for cryo-treatment. Handle 605 is preferably designed with a relatively small profile to facilitate one-handed operation that is agnostic to left hand or right hand preference or gender. Valve switch 606 and actuator switch 607 are positioned separately andpreferably opposite from each other on handle housing 619 to enable surgeon to advance or retract sliding sheath 604 with one finger while activating / deactivating valve switch 606 with another finger while maintaining a stable and precise location of probe tip 602 and / or flexible probe 603 on the target tissue. Alternatively, valve switch 606 and actuator switch 607 may be co-located or integrated (not shown) which may facilitate one finger activation of valve switch 606 and actuation of actuator switch 607. The distal section of handle 605 includes actuator section 618 which provides a space for components that facilitate mechanical, coaxial actuation (e.g., push and pull) of sliding sheath 604 relative to flexible probe 603. As shown in Figure 6a, actuator section 618 tapers to a lower profile from that of handle housing 619 to provide additional space for other instruments that may be used adjacently during a surgical procedure. The distal most portion of actuator section 618 is preferably a tapered conical shaped handle nosecone 617 which prevents snagging or interference with other instruments that may be used adjacently.
[0135] Figure 6C reveals the internal components of cry oprobe 601 with one part of handle housing 619 clamshell removed exposing multiple housing bosses 628 used to align and fasten the clamshell halves. The proximal portion of handle housing 619 includes strain relief 629 which is positioned coaxially over the exterior of exhaust line 608 to relieve stresses between these components and the housing and to secure exhaust line 608 to handle housing 619. Exhaust line 608 is connected to exhaust line adapter 627 located in the distal half of handle housing 619 and is routed separately and distinctly from the various gas transmission components including valve assembly 622 and flexible gas line 626 and exits handle housing 619 at its proximal most end. Flexible gas line 626 is an elongate body with proximal and distal ends and a lumen therethrough, with its distal end connected in fluid communication with valve assembly 622 and its proximal section introduced through the wall and into the inner lumen of exhaust line 608 at the proximal most end of handle housing 619. Although not shown, flexible gas line 626 is sealed about its circumference at the location where it penetrates the wall of exhaust line 608 either by interference / friction alone or via fusing or bonding methods commonly known in the art. Similarly, valve tube 623 is introduced through the wall of exhaust line 608 just proximal to its connection to exhaust line adapter 627 and circumferentially sealed in a similar fashion. Refrigerant gas or liquid can enter cry oprobe 601 via flexible gas line 626. Flexible gas line 626 is capable of carrying a liquid or gas under high pressure, capable of withstanding cryogenic temperatures and also being adequately flexible to accommodate movement of valve assembly 622 whenactuated by switch 606. In addition, the luminal dimension of flexible gas line 626 is sized with sufficiently small dimension to prevent expansion of the cryogen refrigerant. To meet this combination of demanding performance requirements, specialty polymeric or metallic materials must be used including, but not limited to polyimide, PET, PEEK, reinforced polymer tubing, nitinol and the like. Valve assembly 609 is mounted inside the handle housing 619 which is normally biased in a proximal position by spring 620 and can move distally when triggered by valve switch 606. Spring 620 is coaxially oriented over valve tube 623 in between spring backstop 621 and valve assembly 622 and is preferably loaded with a precompression force to help provide the desired bias of valve assembly 622 into the proximal position. In this normal biased proximal position, valve assembly 622 prohibits distal communication of cryogenic liquid or gas it receives from flexible gas line 626. Spring 620 is chosen with a spring constant sufficient to bias valve assembly 622 into the normal proximal position while still being reasonably compressible to move valve assembly 622 distally when leverage is applied by valve switch 606. Spring 620 may be made from metals and plastics well known in the art including, but not limited to stainless steel, nitinol, nylon, polycarbonate and the like. In the embodiment provided herein, valve switch 606 comprises a lever arm which rotates about pivot point 622 and is configured with valve switch arm 606’ that is engaged against the distal end of valve assembly 622 on one side and valve cap 638. Specifically, valve cap 638 comprises a proximal and distal end and lumen therethrough, with said distal end incorporating a flange 638’ and the proximal edge of said flange 638’ is engaged against valve switch arm 606’. This design configuration provides leverage to the surgical operator easing distal movement of valve assembly 622 by helping to overcome the spring force of spring 620.
[0136] The actuation system that enables retraction and advancement of sliding sheath 604 is positioned adjacent to valve assembly 622 and the other previously described gas transmission components within handle housing 619. This actuation system comprises a series of connections between actuator switch 607 and actuator rod 624 which is connected to the proximal end of sliding sheath 604 at the actuator rod sheath junction 625. With this arrangement, proximal and distal movement of actuator switch 607 by a surgical operator correlates directly with proximal and distal movement of sliding sheath 604 thereby allowing precise exposure of flexible probe 603 and tailoring of cryogenic treatment to a specific patient’s anatomy. Actuator switch 607 may include features such as knurling to ease sliding about the handle. Actuator rod 624 is ideally rigid to ensure smooth one to one transmissionof movement from actuator switch 607 to sling sheath 604 while having a low enough profile to fit inside the available envelope of handle housing 619. Actuator rod 624 may be fabricated from metallic or polymeric materials known in the art including, but not limited to stainless steel, nitinol, polycarbonate, acetal or combinations thereof and the like. Actuator rod 624 is attached proximally to actuator switch 607 and distally to sliding sheath 604 using methods commonly known in the art including, but not limited to thermal fusing, adhesive bonding, welding, soldering, insert molding, combinations thereof and the like.
[0137] Figure 6D provides a cross sectional view (Section 6D-6D) of the cryoprobe device 601 provided in Figure 6B and identifies Detail A representing the cross section of cryoprobe valve assembly 622. Figure 6D also identifies Detail B representing the cryoprobe distal segment with sliding sheath 604 of the device fully retracted exposing flexible probe 603 and probe tip 602.
[0138] Figure 6E provides a closeup depiction of cryoprobe valve assembly 622 (referenced in Detail A of Figure 6D) that is mounted in place within proximal housing rib 633 of handle housing 619 with valve assembly 622 able to slidably move axially within proximal housing rib 633. Cryoprobe valve assembly 622 comprises valve housing 639 which contains O-rings 640 and valve cap 638. Valve housing 639 has a proximal and distal end and a lumen therethrough. Valve housing 639 is preferably configured as a cylindrical elongate body comprising a smaller, proximal outer diameter section and a larger, distal outer diameter section. The proximal most end of valve housing 639 includes a flange 636 connected to the smaller, proximal outer diameter section. The larger, distal outer diameter section of valve housing 639 includes one or more set screws 635 that secures valve cap 638 in valve housing 639. Valve housing 639 features a series of interconnected lumens of varying sizes with the largest lumen 637 located at the larger, distal outer diameter section of valve housing 639, continuing to a smaller, intermediate lumen 637’ near the base of the larger, distal outer diameter section and then continuing further to an even smaller proximal lumen 637” within the smaller, proximal outer diameter section. The largest lumen 637 section contains one or more O-rings 640 positioned at its base which provide a hermetic seal between the outer wall of valve tube 623 and inner wall of the largest lumen 637 of valve housing 639.
[0139] The proximal end of elongate valve tube 623 and the distal end of flexible gas line 626 are inserted within the distal largest lumen 637 and proximal smaller lumen 637” ofcryoprobe valve assembly 622, respectively. Valve tube 623 is an elongate member with a proximal and distal ends and lumen therethrough. The proximal end 623’ of valve tube 623 is closed. In addition, the proximal portion of valve tube 623 features orifice 641 which includes one or more holes provided through the wall of valve tube 623 permitting fluid communication with the inner lumen of valve tube 623. As shown in Figure 6E, however, orifice 641 is positioned within O-rings 640 thereby preventing fluid communication with the inner lumen of valve tube 623. The proximal end of valve tube 623 in Figure 6d also shows an inner gas line 632 coaxially positioned within the lumen of valve tube 623 with the two components secured by bond 630, as well as flexible gas line 626 secured to valve assembly 622 via bond 631. Inner gas line 632 is an elongate member with a proximal and distal ends and lumen therethrough. The mechanism of valve assembly 622 also includes spring backstop 621, spring 620 and valve switch arm 606’. Spring backstop 621 is preferably comprised of a thick-walled ring having a proximal and distal end and a lumen therethrough and is coaxially mounted and secured to the outside wall of valve tube 623. Spring backstop 621 provides a means to maintain valve tube 623 in a fixed position inside handle housing 619 by mounting it within distal housing rib 634.
[0140] The various parts and components identified previously can be fabricated using materials and processes well known in the art. Materials include but are not limited to polymeric and metallic materials such as polycarbonate, acetal, nylon, polypropylene, polyethylene, polyethylene terephthalate (PET), polyimide, polyether ether ketone (PEEK), polyether block amide (PEBAX), polyolefin, nitrile rubber, silicone rubber, polyurethane, stainless steel, nitinol, titanium, and the like. Processes include but not limited to injection molding, compression molding, transfer molding, insert molding, extrusion, machining, 3D printing, drawing, necking, dip coating, forming, coil winding, adhesive bonding, welding, soldering, swaging, ultrasonic welding, thermal fusing, lamination, die cutting, die punching, drilling / laser drilling, press fitting, and the like.
[0141] Figure 6F depicts a side plan view of a cryoprobe device 601 with valve switch 606 in the depressed position wherein gas is flowing into the distal segment of the device. In use, the surgeon operator could depress or actuate valve switch 606 with a finger while holding handle 605 steady at or about a tissue (not shown) targeted for ablation. Figure 6G provides a cross sectional view (Section 6G-6G) of cryoprobe device 601 provided in Figure 6F and identifies Detail B representing the cross section of cryoprobevalve assembly 622 after actuation of valve switch 606. Figure 6H provides a closeup depiction of cryoprobe valve assembly 622 referenced in Detail B of Figure 6G. As shown in Figure 6H, actuation of valve switch 606 moves valve switch arm 606’ pushing valve assembly 622 distally overcoming the bias force and compressing spring 620. This action exposes orifice 641 which was originally positioned within and covered by O-rings 640 and thereby permits fluid communication between refrigerant gas or liquid (not shown) received from flexible gas line 626 into intermediate lumen 637’ of valve housing 639 with the inner lumen of valve tube 623.
[0142] Figure 61 provides a closeup depiction of the distal segment of cryoprobe 601 referenced in Detail B of Figure 6D with sliding sheath 604 fully retracted exposing flexible probe 603. Tn this figure, the details of the construction of flexible probe 603 are revealed. Specifically, flexible probe 603 comprises probe tip 602 at its distal most end attached to probe liner 642 which is supported internally by probe coil 643. The proximal end of flexible probe 603 is attached to the distal end of middle tube 646. Inner gas line 632 is disposed along the inner lumen of flexible probe 603 and within probe liner 642 and probe coil 643 with its distal end terminating inside of probe tip 602. Probe tip 602 is preferably comprised of an atraumatic geometry (e.g., dome or bullet shape) and includes a cavity or free space within it. Probe tip 602 is fabricated using thin walled, conductive materials (e.g. metals) to allow and maximize heat exchange with the targeted tissue. Probe liner 642 comprises a tubular member with a proximal and distal end and a lumen therethrough preferably fabricated using thin walled conductive material such as PET, or alternatively metallic materials such as nitinol. The thin walled nature of probe liner 642 confers flexibility which is advantageous in allowing flexible probe 603 to conform with varying anatomies targeted for treatment. In addition, the thin wall reduces the potential for probe liner 642 acting as an insulator and thereby reducing the efficacy of treatment. Probe coil 643 preferably comprises a flat or round wire wound coil with spacing in between coil segments configured to optimize luminal support of probe liner 642, to confer flexibility to flexible probe 603 and to maximize heat exchange. This flexibility also renders flexible probe 603 to be atraumatic as the probe will flex or deflect when facing resistance which can be important to avoid or prevent damage to sensitive structures.
[0143] In use, refrigerant gas or liquid (not shown) which exits the small, terminal lumen of inner gas line 632 into the larger volume inner space of probe tip 602 and into thespace between the outer wall of inner gas line 632 and the inner wall of probe liner 642 results in expansion of the refrigerant gas or liquid generating extremely low (cryogenic) temperatures in probe tip 602 and flexible probe 603.
[0144] Detail B of Figure 61 also reveals the construction of the distal end of sliding sheath 604 which comprises sliding sheath tip 647 which optionally incorporates transition coil 649 which is joined to sliding sheath body 648 via sliding sheath tip junction 651. The geometry of sliding sheath tip 647 is preferably tapered with its distal end having a reduced profile that transitions smoothly to the underlying flexible probe 603 and / or probe tip 602. Besides being atraumatic, this smooth transition reduces or prevents snagging of the device with adjacent tissue during manipulation. Sliding sheath tip 647 is purposefully designed to provide smooth transition between the stiffer sliding sheath body 648 component with the underlying flexible probe 603, thereby preventing kinking or other damage to flexible probe 603 and underlying inner gas line 632, effectively acting as strain relief in bends. Optional transition coil 649 may be included in the wall of sliding sheath tip 647 to enhance kink resistance. Transition coil 649 may be fabricated using a round or flat wire which is wound or potentially a braided structure (not shown) typically known in the art.
[0145] Figure 61 further illustrates malleable tube 650 which facilitates customization of the cryoprobe 601 shape by the surgeon operator. Malleable tube 650 comprises a tubular member with a proximal and distal end and a lumen therethrough, with its proximal end attached to handle 605 (not shown) and its distal end terminating near sliding sheath tip junction 651. Malleable tube 650 may be fabricated from a variety of materials including but not limited to stainless steel, aluminum, copper, etc. which can be plastically deformed to the desired shape and then maintain the shape during a surgical procedure while still facilitating manipulation of tissue. The malleability and customization allow the surgeon operator to position the handle of the device (not shown) such that it does not interfere with adjacent devices (e.g., endoscopes) which may be used during a procedure.
[0146] Finally, middle tube 646 comprises a tubular member with a proximal and distal end and a lumen therethrough, with its proximal end attached to handle 605 (not shown) which is in communication with exhaust line 608 (as shown in Figure 6C) and its distal end attached to the proximal end of flexible probe 603. Middle tube 646 is configured coaxially between the inner lumen of malleable tube 650 and the outer wall of inner gas line 632. Middle tube 646 provides a path for expanded refrigerant gas (not shown) to returntowards the proximal end of cryoprobe 601 and to exit the device via exhaust line 608 (as shown in Figure 6C). Middle tube 646 may be fabricated from a variety of rigid materials including but not limited to stainless steel, aluminum, copper, and the like.
[0147] It should be noted that all materials in the path of refrigerant gas or liquid must be capable of withstanding high pressure associated with the gas source (e.g., refrigerant canister) and must be capable of withstanding cryogenic conditions without significant deterioration.
[0148] Figure 6J provides an exploded isometric view of canister holder 610 of cryoprobe system 600 along with cryogenic gas canister 652 and the proximal segment of cryoprobe 601 device of Figure 6. Canister holder 610 is comprised of canister holder lid 612, hanger 611, lock 613 and canister holder body 614 as previously described in Figure 6A. Canister holder body 614 also features adapter slot 653 located at the bottom or distal aspect of canister holder 610 and is designed to receive canister adapter 609 when inserted via the side wall of canister holder body 614. As shown, canister adapter 609 is attached to and in fluid communication with exhaust line 608. Canister holder body 614 includes a central slot or cavity designed to receive and / or hold gas canister 652. The outer profile of gas canister body 614 is preferably round but may be any suitable geometry easily manipulated by a user. Canister holder lid 612 is pivotably attached to the top or proximal aspect of canister body 614 allowing it to be opened to receive gas canister 615 and subsequently closed when desired by the user. Canister holder lid 612 includes a lip which can engage with lock 613 wherein fastening of the lock advances and compresses gas canister 652 against canister adapter 609. In one embodiment, canister holder 610 of Figure 6.T may be fabricated using materials well known in the art that may be sterilized, cleaned and re-sterilized multiple times. These materials include, but are not limited to stainless steel, titanium, anodized aluminum, and the like. Alternatively, canister holder may be fabricated using materials that are sterilizable and then can be disposed after use in a surgical procedure. These materials include, but are not limited to metals such as stainless steel, titanium, anodized aluminum, and the like and polymeric materials such as polycarbonate, acetal, Teflon, PEEK, acrylic, combinations thereof, and the like.
[0149] Figures 6K and 6L depict front and side views, respectively, of the components provided in Figure 6J after the canister adapter 609 on the proximal segment of cryoprobe 601 has been slid into adapter slot 653 and cryogenic gas canister 652 has beenloaded and secured within detachable canister holder 610. As shown in Figure 6K, canister holder lid 612 has been fully secured (e.g., completely closed) to the canister holder body 614 via lock 613 which has engaged with the lip 612’ feature of canister holder lid 612. As lock 613 is engaged with this lip feature and being closed to a locked position, canister holder lid 612 pushes gas canister 652 towards canister adapter 609 and punctures gas canister 652 (not shown) thereby allowing fluid communication of the cryogen with cryoprobe 601. The side view in Figure 6L illustrates lever arm 613’ of lock 613 positioned by a user such that canister holder lid 612 is fully secured via engagement with lip 612’.
[0150] Figure 6M provides a cross sectional view of the canister holder referenced in Section 6M-6M of Figure 6K. In this illustration, Detail D provides an internal view of canister holder body 614 with gas canister 652 fully engaged with canister adapter 609 after canister holder lid 612 has been fully secured to canister holder body 614 via lock 613 as previously described in Figures 6K and 6L.
[0151] Figure 6N provides a closeup depiction of Detail D of Figure 6M wherein cryogenic gas canister 652 is engaged with canister adapter 609 within canister holder body 614 thereby placing the cryogen contents of gas canister 652 in fluid communication with cryoprobe 601 (not shown). In this illustration, piercing element 654 has penetrated the distal tip or nose of gas canister 652 facilitating access or said communication to any cryogen gas contained within it. Canister adapter 609 comprises piercing element 654, optional piercing element O-ring 657, O-ring 640, desiccant 655, filter 656, and screen mesh 665. Optional piercing element O-ring 657 is positioned in between gas canister 652 and piercing element 654 to prevent cryogen gas from gas canister 652 from leaking around piercing element 654. O-ring 640 is mounted over the opposite side of piercing element 654 to prevent cryogen gas from leaking out of canister adapter 609. Canister adapter 609 includes canister adapter chamber 658 which comprises a free space that may be filled with a desiccant 655 which is positioned in between the cryogen source (e.g., gas canister 652) and cryoprobe 601 (not shown) and serves to reduce / remove any residual moisture contained in the fluid path which may potentially impede the flow of cryogen gas by freezing within flexible gas line 626 and / or within other fluid communicating components of the system. Desiccant 655 may comprise pellets, beads or other forms or shapes of desiccant material well known in the art. Preferably, desiccant 655 may be made of CaSO4 (Calcium Sulfate- Anhydrous) material with a size range between 10 to 20 mesh. One or more filters 656 maybe positioned distal to desiccant 655 within adapter chamber 658 to reduce or prevent any particulates from impeding the flow of cryogen gas into cryoprobe 601 (not shown). Filter 656 material may be fabricated using materials well known in the art including, but not limited to polymer or copolymer membrane materials such as Teflon, polypropylene, nylon, acrylic, etc. preferably in the form of a microporous or macroporous structure. Filter 656 may have a pore size ranging from 0.2 to 5.0 microns and preferably in the range of 1 to 3 microns and more preferably 3 microns. Optionally, a screen mesh 665 may be positioned at the bottom of adapter chamber 658 distal to filter 656 to provide additional reinforcement to filter 656 as filter 656 may be damaged and / or shed particulate in the face of the high pressure cryogen. As shown in Figure 6N, the proximal end of flexible gas line 626 and exhaust line 608 are attached to the distal end of canister adapter 609 with flexible gas line bond 666 and exhaust line bond 667, respectively, which may be accomplished via adhesive bonding, heat fusing, or other processing methods well known in the art. The closeup depiction of Detail D in Figure 6N also highlights exhaust ports 615 which facilitates exhausting of cryogenic gas used in cry oprobe 601 to the atmosphere as previously described. Exhaust ports 615 are positioned in the proximal segment of exhaust line 608 and may comprise a notch, punch holes, drilled holes or openings created using processes and methods well known in the art.
[0152] Figure 7A depicts an alternative embodiment of cryoprobe system 700 comprised of cryoprobe 601 connected to a remote, integrated canister holder 701 via exhaust line 608 of cry oprobe 601. Unlike the detachable canister holder 610 of cry oprobe system 600 provided in Figure 6A, all components of the system are integrated such that the end user only needs to insert a cryogen gas canister (not shown) into integrated canister holder 701 and simply attach and tighten integrated canister holder cap 703 to integrated canister holder body 702 to pierce the gas canister (not shown) to prepare the system for use. Although not shown, the ablation effector for cryoprobe system 700 also comprises probe tip 602 and flexible probe 603, as well as malleable tube 650 all of which were previously described for cryoprobe system 600. This embodiment enhances simplicity and ease of use and may be fully disposable.
[0153] Figure 7B provides an exploded plan view of the remote, integrated canister holder 701 of Figure 7A and its related components including integrated canister holder cap 703 (e.g., cap 703), integrated canister adapter 705 (e.g., adapter 705) and integrated canisterholder body 702. Cap 703 has internal geometry that generally matches the proximal geometry of gas canister 706. The inside of cap 703 comprises a female thread (not shown) that mates with body thread 707. Cap 703 may also have external features including hanger 704 which may be used to temporarily mount or attach integrated canister holder 701 to an IV pole or bedside, as required after it has been prepared as well as surface features intended to help an end user properly grip cap 703 when attaching or detaching to integrated canister holder body 702. In this embodiment, integrated canister adapter 705 which is connected to exhaust line 608 is designed to be mounted inside the distal potion of integrated canister holder body 702. Integrated canister holder body 702 features body thread 707 that mates with the thread feature of cap 703 and is designed with an internal geometry that can receive integrated canister adapter 705 and gas canister 706 within it.
[0154] Figure 7C is a close-up, cross sectional view of the remote, integrated canister holder of Figure 7A and its related components after the gas canister has been activated (e.g., positioned in fluid communication with cry oprobe 601 (not shown) via integrated canister adapter 705 after cap 703 has been tightened to integrated canister holder body 702 using body thread 707 and cap thread 714. As previously described for the detachable canister holder embodiment in Figure 6N, integrated canister adapter 705 is constructed with a similar design featuring a piercing element 711, O-ring 713 and adapter chamber 712 that contains a desiccant 708 in series with one or more filters 709 and an optional screen mesh 710 which are intended to function as previously described. However, this configuration of the embodiment includes additional components such as adapter plug O-ring 717 mounted against screen mesh 710 and secured in place to integrated canister adapter 705 by adapter plug 716. Adapter plug O-ring 717 prevents cryogen gas from leaking about filter 709 and also from leaking through the junction between integrated canister adapter 705 and adapter plug 716. The distal end of adapter plug 716 is connected to exhaust line fitting 719 which includes distal adapter plug O-ring 718 that prevents cryogen gas from leaking through the junction between adapter plug 716 and the exhaust line fitting 719 located inside of the distal end of integrated canister holder body 702. Exhaust line fitting 719 also features exhaust ports 715 where the cryogen gas circulated through exhaust line 608 of cryoprobe 601 (not shown) can exhaust to the atmosphere. The series of components provided in the distal segment of integrated canister holder body 702 (e.g., piercing element 711, integrated canister adapter 705, adapter plug 716, and exhaust line fitting 719) all include through lumens which facilitate fluid communication from gas canister 706 after it has been piercedor activated to and through flexible gas line 626. These various components may be fabricated using polymeric and / or metallic materials well known in the art including but not limited to polymeric materials such as ABS, polycarbonate, acetal, polypropylene, nylon, polyethylene, or combinations thereof, as well as metallic materials such as stainless steel, brass, aluminum, titanium, and the like. Also, these various components may be produced using a variety of processing methods including but not limited to injection molding, machining, stamping, swaging, and the like.
[0155] Figures 8A through 8C illustrates the versatility of cryoprobe system 600 or 700 of the invention with respect to cryoablation of small discrete tissue segments up to more significant areas of tissue by user adjusted manipulation of sliding sheath 604 relative to flexible probe 603. Specifically, Figure 8 A depicts a cryogenic probe component of the system of the invention with sliding sheath tip 647 fully advanced to probe tip 602 with said probe tip 602 engaged against tissue 801 targeted for cryoablation treatment. In this configuration, cry oprobe 601 functions as a straight cry oprobe ideal for treating tissue directly ahead of the device when the operator has enough room to manipulate said straight device in a cavity or space to create cryo-ablated tissue 802 or any other focal lesion. In some instances, the anatomy may be more constrained and the tissue targeted may be more difficult to reach and / or also a larger surface area may need to be treated. To address this, sliding sheath 604 may be partially retracted to expose a portion of flexible probe 603 just beyond sliding sheath tip 647 with the exposed segment of flexible probe 603 engaged against and ideally conforming to tissue 801 targeted for cryoablation treatment as shown in Figure 8B. In this figure, sliding sheath tip 647 is illustrated to be slightly deflected and is designed to provide smooth transition to flexible probe 603 when deflected against tissue 801. For example, the sliding sheath tip 647 may deflect relative to the sheath such that the sheath tip 647 transitions the flexible probe 603 of the ablation effector into an arcuate configuration which conforms to an underlying region of tissue when the sheath is retracted. The flexibility of sliding sheath tip 647 also prevents kinking of flexible probe 603 relative to sliding sheath 604 while probe tip 602 is pressed against tissue 801. The combination of the flexibility conferred by sliding sheath tip 647 and flexible probe 603 enables flexible probe 603 to conform to a variety of anatomical shapes and contours, maximizing the surface area of contact and heat exchange with target tissue 801 yielding clinically desired cryoablated tissue 802. As noted previously, sliding sheath 604 provides versatility to the user to adjust the amount of exposed portion of flexible probe 603 as clinically desired or requiredbased upon anatomical constraints and other specific requirements of the patient. Figure 8C demonstrates this versatility by illustrating a full retraction of sliding sheath 604. By fully retracting sliding sheath 604, the longest segment of flexible probe 603 is exposed and conformed with tissue 801 further maximizing the surface area of contact and the concurrent ablation of tissue 802. It should be obvious based upon Figures 8A to 8C and based upon the descriptions herein that a user can tailor the amount of exposure of flexible probe 603 as desired using actuator switch 607 previously described in Figure 6A. This tailoring can occur before the device is inserted or used in a patient (e.g. at the bedside) or interprocedurally when the device has been positioned at or near tissue 801 targeted for cryoablation treatment.
[0156] Figure 9 outlines a step-by-step method to use the devices and systems described in this invention to treat diseases via neuroablation in the tympanic cavity as follows: a. Consult with the patient and ascertain that the patient is a candidate for the current procedure, b. Apply necessary anesthesia, c. Create access to the inside of the tympanic cavity, d. Navigate the distal end of the device through the external ear canal and into the tympanic cavity under direct visualization, e. Identify the target nerve or nerves within the tympanic cavity under direct visualization, f. Position the ablation effector at the distal end of the device on the desired location on the nerve trajectory and in direct contact with all or a portion of said nerve or nerves under direct visualization, g. Ablate all or a portion of said nerve or nerves, h. Stop the ablation procedure once the desired amount of ablation of the target nerve or nerves is completed, i. Repeat steps “e” to “h” of this method as required to further ablate the same or different nerve or nerves in the tympanic cavity, j. Retract the device out of the tympanic cavity and through the external ear canal to remove said device from the patient. k. Repair the access site as necessary.While individual steps are illustrated and described in Figure 9, some of the steps may be optionally omitted in other embodiments and / or taken in a different order as desired or necessary. Furthermore, any combination of device features described may be used in any of the methods described in any number of combinations.
[0157] Figure 10 outlines a step-by-step method to use cryoprobe devices and systems 600 or 700 of the invention to treat diseases via neuroablation in the tympanic cavity as follows: a. Consult with the patient and ascertain that the patient is a candidate for the current procedure, b. Apply necessary anesthesia, c. Optionally, shape the malleable tube component of the cryoprobe to the desired shape or configuration, d. Create access to the inside of the tympanic cavity and position cryoprobe at or about the nerve or nerves targeted for ablation under visualization, e. Position the ablation effector (e.g. the probe tip, or optionally the probe tip and a portion or all of the flexible probe via retraction of the sliding sheath) of the cryoprobe on the desired location on the nerve trajectory and in direct contact with all or a portion of said nerve or nerves under visualization, f. Ablate all or a portion of said nerve or nerves, g. Optionally, advance or retract the sliding sheath, reposition the ablation effector in direct contact with all or a portion of said nerve or nerves under visualization and ablate all or a portion of said nerve or nerves, h. Stop the ablation procedure once the desired amount of ablation of the target nerve or nerves is completed, i. Repeat steps “e” to “h” of this method as needed to further ablate the same or different nerve or nerves in the tympanic cavity, j. Remove the cry oprobe from the tympanic cavity of the patient. k. Repair the access site to the tympanic cavity as necessary.
[0158] While individual steps are illustrated and described in Figure 10, some of the steps may be optionally omitted in other embodiments and / or taken in a different order as desired or necessary. Furthermore, any combination of device features described may be used in any of the methods described in any number of combinations.
[0159] Prior to the ablation procedure, the physician might conduct a diagnostic procedure to ensure of the suitability of the ablation target. In some embodiments such diagnostic step might include injecting or applying an anesthetic to the target location.
[0160] Direct visualization includes but not limited to using an endoscopes, rigid or flexible, or a microscope.
[0161] In one embodiment of the method, the device includes or directly incorporates the visualization and / or illumination components. In another embodiment separate visualization and / or illumination instruments or tools are used.
[0162] In one embodiment of the method, in order to access the tympanic cavity, an incision is made on the tympanic membrane. In another embodiment, an incision is made in the external ear canal in the proximity of the tympanic membrane to elevate a tympanomeatal flap to provide access to the tympanic cavity. In another embodiment facial recess approach is used to access the tympanic cavity.
[0163] In one embodiment of the methods, the device includes a cutting component that can be used to create access to tympanic cavity, thereby combining the elements of steps c and d provided in Figure 9.
[0164] In one embodiment of the method described herein, the step to identify the target nerve or nerves can include using a nerve tissue visualization aid (e.g. dyes) or other techniques to distinguish nerve tissue from surrounding tissues. In another embodiment, the step to identify target nerve includes methods of nerve stimulation or nerve monitoring commonly known in the art.
[0165] In one embodiment of the method contemplated in this invention, the ablation effector component of the device is a cry oprobe that can provide temperatures in the range of, e.g., -20°C to -100°C to effect cryoablation of the main branch of the tympanic nerve and / or the tympanic plexus located on or near the promontory of the tympanic cavity of a patient. In this example, the method and devices described herein are used to treat dysfunctions and / or diseases including, but not limited to referred otalgia (e.g. otalgia from TMJ disorders), otic neuralgia, glossopharyngeal neuralgia, headache such as migraine, parotid gland fistula, parotitis, drooling, autonomic dysfunction and / or the Frey syndrome.
[0166] In another embodiment of the method contemplated in this invention, the ablation effector component of the device is a cryoprobe that can provide temperatures in the range of -20°C to -100°C degrees to effect cryoablation of the chorda tympani nerve located in the tympanic cavity of a patient. In this example, the method and devices described herein are used to treat dysfunctions and / or diseases including, but not limited to taste disturbances, such as autonomic dysfunction, hypogeusia, ageusia or dysgeusia, excessive drooling, retronasal olfaction, or orosensory hyperactivity such as burning mouth syndrome.
[0167] In another embodiment of the method contemplated in this invention, the ablation component of the device is a cryoprobe that uses temperatures in the range of -20°C to -100°C degrees to effect cryoablation of both the chorda tympani nerve and the tympanic nerve located in the tympanic cavity of a patient for example to treat obesity.
[0168] In another embodiment of the method contemplated in this invention, the ablation component of the device is a cryoprobe that uses temperatures in the range of -20°C to -100°C degrees to effect cryoablation of Arnold’s nerve.
[0169] After the cryoablation of the target nerve, the patient will lose the function of that nerve for a period of time, after which the nerve is expected to regenerate into healthy tissue or nerve tissue exhibiting substantially less dysfunction than prior to the ablation procedure. In some patients, it might be necessary to repeat the procedure to improve efficacy or to extend the duration of the ablative (therapeutic) effects on the targeted nerve or nerves.
[0170] Other medical therapies such as use of pharmaceutical agents can be conducted in combination with the methods described herein in order to improve the clinical outcomes of the patient.
[0171] It is expressly contemplated that different features between different embodiments and methods may be combined in any number of combinations to result in different embodiments of the devices and methods.
[0172] The applications of the devices and methods discussed herein are not limited to but may include any number of further treatment applications. Moreover, such devices and methods may be applied to other treatment sites within the body. Modification of the above-described assemblies and methods for carrying out the invention, combinationsbetween different variations as practicable, and variations of aspects of the invention that are obvious to those of skill in the art are intended to be within the scope of the claims.
Claims
CLAIMSWhat is claimed is:
1. A cry oprobe system, comprising: an elongate probe connected at a proximal end to a handle and having an ablation effector at a distal end, wherein the ablation effector defines a lumen such that the ablation effector is configured to conduct cryogenic energy when a cryogen flows within the lumen; a sheath slidably positioned over the elongate probe and having a sheath tip which is configured to deflect relative to the sheath, wherein the sheath tip transitions the ablation effector into an arcuate configuration which conforms to an underlying tissue region when the sheath is retracted; an exhaust line fluidly coupled to the elongate probe; and a reservoir holder fluidly coupled to the exhaust line and configured to retain a removable reservoir of cryogen which is in fluid communication with the lumen defined by the ablation effector.
2. The system of claim 1 further comprising a piercing element positioned within the reservoir holder and configured to pierce into the removable reservoir of cryogen to release a flow of the cryogen into the lumen.
3. The system of claim 2 further comprising a dessicant positioned distal to the piercing element.
4. The system of claim 2 further comprising one or more filters positioned distal to the piercing element.
5. The system of claim 4 wherein the one or more filters have a pore size ranging from 0.2 to 5.0 microns.
6. The system of claim 4 wherein the one or more filters have a pore size ranging from 1 to 3 microns.
7. The system of claim 1 wherein the ablation effector defines a tip which is configured to conduct cryogenic energy when the cryogen flows within the lumen.
8. The system of claim 1 wherein the reservoir holder further comprises a holder body configured to retain the reservoir of cryogen and a holder cap configured to be secured over the holder body.
9. The system of claim 1 wherein the reservoir holder further comprises a mechanism for mounting or attaching the reservoir holder.
10. The system of claim 1 wherein the reservoir holder is configured to maintain an upright orientation of the reservoir of cryogen within.
11. The system of claim 1 wherein the handle comprises an actuator for releasing the cryogen within the lumen.
12. A method of treating a tissue region within a tympanic cavity, comprising: advancing an elongate probe having an ablation effector at a distal end into proximity of a nerve trajectory within a tympanic cavity; retracting a sheath having a sheath tip slidably positioned over the elongate probe to deploy the ablation effector; conforming the ablation effector against at least a portion of the nerve trajectory such that the sheath tip deflects relative to the sheath and transitions the ablation effector into an arcuate configuration against the portion of the nerve trajectory; introducing a cryogen into a lumen defined through the ablation effector such that the ablation effector conducts cryogenic energy and ablates the portion of the nerve trajectory.
13. The method of claim 12 wherein advancing the elongate probe further comprises visualizing within the tympanic cavity.
14. The method of claim 12 further comprising repositioning the elongate probe relative to the portion of the nerve trajectory.
15. The method of claim 12 further comprising ablating the portion of the nerve trajectory via a tip of the ablation effector prior to retracting the sheath.
16. The method of claim 12 wherein introducing the cryogen into the lumen further comprises piercing a removable reservoir of cryogen in fluid communication with the elongate probe.
17. The method of claim 16 further comprising passing the cryogen through a dessicant prior to introduction through the elongate probe.
18. The method of claim 16 further comprising passing the cryogen through one or more filters prior to introduction through the elongate probe.
19. The method of claim 12 wherein introducing the cryogen into the lumen further comprises releasing the cryogen from a reservoir of cryogen retained within a holder body and holder cap configured to be secured over the holder body.
20. The method of claim 12 wherein introducing the cryogen into the lumen further comprises maintaining a reservoir of cryogen in an upright orientation.
Citation Information
Patent Citations
Methods of cardiac ablation employing a deflectable sheath catheter
US20050222558A1
Cryogenic Probe Filtration System
US20130184694A1
Apparatus and methods for regulating cryogenic treatment
US20150289920A1
Endovascular catheters and methods for carotid body ablation
WO2013163322A1
